JP2017512789A - ジヒドロピリミジン化合物及び医薬におけるその適用 - Google Patents
ジヒドロピリミジン化合物及び医薬におけるその適用 Download PDFInfo
- Publication number
- JP2017512789A JP2017512789A JP2016558407A JP2016558407A JP2017512789A JP 2017512789 A JP2017512789 A JP 2017512789A JP 2016558407 A JP2016558407 A JP 2016558407A JP 2016558407 A JP2016558407 A JP 2016558407A JP 2017512789 A JP2017512789 A JP 2017512789A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- methyl
- thiazol
- title compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QXIAGKWWKMKVLE-VIFPVBQESA-N CC(C)(C)OC(N1C[C@H](CCC(O)=O)OCC1)=O Chemical compound CC(C)(C)OC(N1C[C@H](CCC(O)=O)OCC1)=O QXIAGKWWKMKVLE-VIFPVBQESA-N 0.000 description 1
- DYGCSUICELQJIO-COBSHVIPSA-N CC(C[C@H]1OCCNC1)C(O)=O Chemical compound CC(C[C@H]1OCCNC1)C(O)=O DYGCSUICELQJIO-COBSHVIPSA-N 0.000 description 1
- 0 CC(C[C@]1OCC[Zn]C1)C(*)=O Chemical compound CC(C[C@]1OCC[Zn]C1)C(*)=O 0.000 description 1
- OGUVUOIKRVWUDL-ZDUSSCGKSA-N CC(NC(c1ncc[s]1)=N[C@H]1c(c(Cl)c2)ccc2Cl)=C1C(OC)=O Chemical compound CC(NC(c1ncc[s]1)=N[C@H]1c(c(Cl)c2)ccc2Cl)=C1C(OC)=O OGUVUOIKRVWUDL-ZDUSSCGKSA-N 0.000 description 1
- ZRKFCDVMSWDCFX-UHFFFAOYSA-N CCC(C)CCCC(C(C)I)[ClH]CC Chemical compound CCC(C)CCCC(C(C)I)[ClH]CC ZRKFCDVMSWDCFX-UHFFFAOYSA-N 0.000 description 1
- ILFIXUVIBJYIDE-VFNWGFHPSA-N CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O ILFIXUVIBJYIDE-VFNWGFHPSA-N 0.000 description 1
- XOYWJUFEMRHPBF-VFNWGFHPSA-N CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O XOYWJUFEMRHPBF-VFNWGFHPSA-N 0.000 description 1
- GTVGTNQWQJLDEG-BTYIYWSLSA-N CCOC(C1=C(CN2[C@@H](CCC(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CCOC(C1=C(CN2[C@@H](CCC(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O GTVGTNQWQJLDEG-BTYIYWSLSA-N 0.000 description 1
- KJKXMYQMOZCMRZ-VXGBXAGGSA-N CCOC(CC[C@H]([C@@H](C)OCC1)N1C(OC(C)(C)C)=O)=O Chemical compound CCOC(CC[C@H]([C@@H](C)OCC1)N1C(OC(C)(C)C)=O)=O KJKXMYQMOZCMRZ-VXGBXAGGSA-N 0.000 description 1
- ONELXRQCJBCEOV-ZDUSSCGKSA-N COC(C1=C(CBr)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O Chemical compound COC(C1=C(CBr)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O ONELXRQCJBCEOV-ZDUSSCGKSA-N 0.000 description 1
- CCVSZMHYKHZCJN-JLTOFOAXSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@@H]1c(c(Cl)c1)ccc1F)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@@H]1c(c(Cl)c1)ccc1F)=O CCVSZMHYKHZCJN-JLTOFOAXSA-N 0.000 description 1
- SKHFPNFIHFVECE-VLIAUNLRSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O SKHFPNFIHFVECE-VLIAUNLRSA-N 0.000 description 1
- BWVKMHFWCULXRS-VLIAUNLRSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O BWVKMHFWCULXRS-VLIAUNLRSA-N 0.000 description 1
- HJLJZZITBHJBPM-FPSMJMQUSA-N C[C@@H]1OCCN(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3F)=C2C(OC)=O)[C@H]1CCC(O)=O Chemical compound C[C@@H]1OCCN(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3F)=C2C(OC)=O)[C@H]1CCC(O)=O HJLJZZITBHJBPM-FPSMJMQUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410126202 | 2014-03-28 | ||
| CN201410126202.0 | 2014-03-28 | ||
| CN201410596489.3 | 2014-10-29 | ||
| CN201410596489 | 2014-10-29 | ||
| PCT/CN2015/075299 WO2015144093A1 (en) | 2014-03-28 | 2015-03-27 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512789A true JP2017512789A (ja) | 2017-05-25 |
| JP2017512789A5 JP2017512789A5 (cg-RX-API-DMAC7.html) | 2018-04-19 |
Family
ID=54160517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558407A Pending JP2017512789A (ja) | 2014-03-28 | 2015-03-27 | ジヒドロピリミジン化合物及び医薬におけるその適用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9771358B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3122747B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017512789A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160133563A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104945395B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015236982B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2938050A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016012573A (cg-RX-API-DMAC7.html) |
| MY (1) | MY196243A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2682672C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201605896WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015144093A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200032098A (ko) * | 2017-06-26 | 2020-03-25 | 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 |
| JP2021523880A (ja) * | 2018-05-16 | 2021-09-09 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | ジヒドロピリミジン化合物の固体形態及びその調製方法及びその使用 |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190007106A (ko) | 2011-12-21 | 2019-01-21 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| KR102271574B1 (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
| SI2961732T1 (sl) | 2013-02-28 | 2017-07-31 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B |
| PT2981536T (pt) | 2013-04-03 | 2017-08-09 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida e sua utilização como medicamentos para o tratamento da hepatite b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| US10160743B2 (en) | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| SG11201600522UA (en) | 2013-07-25 | 2016-02-26 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| NZ717629A (en) | 2013-10-23 | 2021-12-24 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| CA2927373C (en) | 2013-11-27 | 2021-07-13 | Sunshine Lake Pharma Co., Ltd. | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
| CN110483484A (zh) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| EA201792069A1 (ru) | 2015-03-19 | 2018-04-30 | Новира Терапьютикс, Инк. | Производные азокана и азонана и способы лечения инфекций гепатита в |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| HK1259410A1 (zh) | 2015-09-29 | 2019-11-29 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| EP3426245B1 (en) | 2016-03-07 | 2022-12-14 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CA3021068A1 (en) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
| WO2017198201A1 (en) * | 2016-05-19 | 2017-11-23 | Sunshine Lake Pharma Co., Ltd. | Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine |
| EP3468561A4 (en) | 2016-06-10 | 2019-12-04 | Enanta Pharmaceuticals, Inc. | ANTIVIRAL AGENTS AGAINST HEPATITIS B |
| CN107674072B (zh) * | 2016-08-01 | 2020-11-24 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物及其酸加成物的制备方法 |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| CA3037218A1 (en) | 2016-11-18 | 2018-05-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| AU2018291688B2 (en) | 2017-06-27 | 2022-02-03 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections |
| UY37861A (es) | 2017-08-28 | 2019-03-29 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b |
| MA50524A (fr) | 2017-11-02 | 2020-09-09 | Aicuris Gmbh & Co Kg | Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb) |
| BR112020008765A2 (pt) | 2017-11-02 | 2020-10-20 | Aicuris Gmbh & Co. Kg | indol-2-carboxamidas pirazolo-piperidina substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv) |
| US10428070B2 (en) | 2017-12-06 | 2019-10-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| TW201936192A (zh) | 2017-12-06 | 2019-09-16 | 美商因那塔製藥公司 | B 型肝炎抗病毒試劑 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| KR20200131816A (ko) | 2018-03-14 | 2020-11-24 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 캡시드 조립 조절제 투약 요법 |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN109021015B (zh) * | 2018-07-12 | 2019-12-03 | 山东大学 | 二氢嘧啶-磷酰胺类衍生物及其制备方法与应用 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| AR116948A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| WO2020089460A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) |
| UY38437A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) |
| KR102819704B1 (ko) | 2018-11-21 | 2025-06-11 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스제로서의 작용화된 헤테로사이클 |
| TW202035412A (zh) * | 2018-12-20 | 2020-10-01 | 比利時商健生藥品公司 | 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法 |
| BR112021015618A2 (pt) | 2019-02-22 | 2021-10-05 | Janssen Sciences Ireland Unlimited Company | Derivados de amida úteis no tratamento da infecção pelo hbv ou doenças induzidas pelo hbv |
| MX2021013086A (es) | 2019-04-30 | 2021-11-17 | Aicuris Gmbh & Co Kg | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb). |
| WO2020221811A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| KR20220004131A (ko) | 2019-04-30 | 2022-01-11 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 대해 활성인 신규 인돌-2-카르복스아미드 |
| WO2020221824A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
| TW202108576A (zh) | 2019-05-06 | 2021-03-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2020255015A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN110615797A (zh) * | 2019-10-11 | 2019-12-27 | 李丽丽 | 用于治疗乙型肝炎的化合物及其用途 |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| AU2021403827B2 (en) | 2020-12-17 | 2024-07-25 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| EP4289842A4 (en) | 2021-02-05 | 2025-01-08 | Hepagene Therapeutics (HK) Limited | Phenyldihydropyrimidine compound and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014029193A1 (en) * | 2012-08-24 | 2014-02-27 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| WO2014037480A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0202654A3 (en) | 1985-05-20 | 1987-12-16 | E.R. Squibb & Sons, Inc. | 5-carboxy-1,4-dihydropyrimidine derivatives |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| CN101104617B (zh) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| WO2008154818A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution fluorophényle |
| CN101328169B (zh) | 2007-06-18 | 2011-05-25 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| PT2159224E (pt) * | 2007-06-18 | 2012-10-24 | Sunshine Lake Pharma Co Ltd | Tiazolil dihidropirimidinas substituídas com bromo-fenilo |
| CN101328168B (zh) | 2007-06-18 | 2011-09-07 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| CN101575318B (zh) | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| US9487534B2 (en) | 2011-08-02 | 2016-11-08 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| CN104302626B (zh) | 2012-01-06 | 2016-09-07 | 爱尔兰詹森科学公司 | 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途 |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN103664897B (zh) | 2012-09-01 | 2018-04-03 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664925B (zh) | 2012-09-07 | 2018-01-23 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CN103664899B (zh) | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| US20150292045A1 (en) | 2012-11-09 | 2015-10-15 | Indiana University Research And Technology Corporation | Alternative uses for hbv assembly effectors |
| WO2014153459A2 (en) | 2013-03-20 | 2014-09-25 | Indiana University Research And Technology Corporation | Fluorescent-hap: a diagnostic stain for hbv cores in cells |
| PE20151951A1 (es) | 2013-05-17 | 2015-12-26 | Hoffmann La Roche | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b |
| CA2920415A1 (en) | 2013-11-19 | 2015-05-28 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| CN104650069B (zh) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
| CN104650070B (zh) | 2013-11-25 | 2018-09-14 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CA2927373C (en) * | 2013-11-27 | 2021-07-13 | Sunshine Lake Pharma Co., Ltd. | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| RS58384B1 (sr) | 2014-03-07 | 2019-04-30 | Hoffmann La Roche | Novi 6-fuzionisani heteroarildihidropirimidini za lečenje i profilaksu infekcije virusom hepatitisa b |
| ES2687606T3 (es) | 2014-05-30 | 2018-10-26 | Qilu Pharmaceutical Co., Ltd. | Derivado de bucle de dihidropirimido como inhibidor de HBV |
-
2015
- 2015-03-27 SG SG11201605896WA patent/SG11201605896WA/en unknown
- 2015-03-27 CN CN201510141969.5A patent/CN104945395B/zh active Active
- 2015-03-27 EP EP15769748.3A patent/EP3122747B1/en active Active
- 2015-03-27 KR KR1020167029448A patent/KR20160133563A/ko not_active Withdrawn
- 2015-03-27 MX MX2016012573A patent/MX2016012573A/es unknown
- 2015-03-27 CA CA2938050A patent/CA2938050A1/en not_active Abandoned
- 2015-03-27 WO PCT/CN2015/075299 patent/WO2015144093A1/en not_active Ceased
- 2015-03-27 JP JP2016558407A patent/JP2017512789A/ja active Pending
- 2015-03-27 RU RU2016138735A patent/RU2682672C2/ru active
- 2015-03-27 MY MYPI2016702906A patent/MY196243A/en unknown
- 2015-03-27 AU AU2015236982A patent/AU2015236982B2/en active Active
- 2015-03-27 US US15/116,226 patent/US9771358B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014029193A1 (en) * | 2012-08-24 | 2014-02-27 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| WO2014037480A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
Non-Patent Citations (3)
| Title |
|---|
| 光学異性体の分離（季刊 化学総説 NO.6）, JPN6011000511, 1989, pages 2 - 5, ISSN: 0003988203 * |
| 加藤隆一: "光学異性薬物の研究の流れ", 薬事, vol. 第２９巻、第１０号, JPN3011000611, 1 October 1987 (1987-10-01), JP, pages 2039 - 2042, ISSN: 0003988202 * |
| 山中 宏、宮崎 浩、村上尚道: "光学活性体のプレパレーション・生理活性・利用", 季刊 化学総説 光学異性体の分離, JPN3011000610, 10 June 1999 (1999-06-10), JP, pages 8 - 9, ISSN: 0003988201 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200032098A (ko) * | 2017-06-26 | 2020-03-25 | 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 |
| JP2020525453A (ja) * | 2017-06-26 | 2020-08-27 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | ジヒドロピリミジン化合物、及び医薬におけるその使用 |
| JP7260488B2 (ja) | 2017-06-26 | 2023-04-18 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | ジヒドロピリミジン化合物、及び医薬におけるその使用 |
| KR102665544B1 (ko) | 2017-06-26 | 2024-05-14 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 |
| JP2021523880A (ja) * | 2018-05-16 | 2021-09-09 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | ジヒドロピリミジン化合物の固体形態及びその調製方法及びその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201605896WA (en) | 2016-08-30 |
| EP3122747A1 (en) | 2017-02-01 |
| EP3122747B1 (en) | 2020-05-20 |
| US20160347746A1 (en) | 2016-12-01 |
| RU2682672C2 (ru) | 2019-03-20 |
| US9771358B2 (en) | 2017-09-26 |
| CN104945395B (zh) | 2018-01-23 |
| KR20160133563A (ko) | 2016-11-22 |
| CA2938050A1 (en) | 2015-10-01 |
| EP3122747A4 (en) | 2017-11-15 |
| MX2016012573A (es) | 2018-02-19 |
| RU2016138735A (ru) | 2018-05-03 |
| AU2015236982A1 (en) | 2016-08-11 |
| CN104945395A (zh) | 2015-09-30 |
| AU2015236982B2 (en) | 2017-12-14 |
| MY196243A (en) | 2023-03-24 |
| RU2016138735A3 (cg-RX-API-DMAC7.html) | 2018-05-03 |
| WO2015144093A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2682672C2 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| RU2678990C1 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| RU2655914C9 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| KR102667040B1 (ko) | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 | |
| HK1228400A1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1228400B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1224286B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1206027B (en) | 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives as hepatitis b virus (hbv) polymerase inhibitors for the treatment of e.g. chronic hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181016 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181011 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190107 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190305 |